HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

AuthorsJeffrey Cummings
JournalBiological psychiatry (Biol Psychiatry) Vol. 68 Issue 10 Pg. 876-8 (Nov 15 2010) ISSN: 1873-2402 [Electronic] United States
PMID21035622 (Publication Type: Journal Article)
Chemical References
  • Amyloid
  • Azepines
  • N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
  • Amyloid Precursor Protein Secretases
  • Alanine
Topics
  • Alanine (adverse effects, analogs & derivatives, therapeutic use)
  • Alzheimer Disease (drug therapy)
  • Amyloid (drug effects)
  • Amyloid Precursor Protein Secretases (antagonists & inhibitors)
  • Azepines (adverse effects, therapeutic use)
  • Cognition Disorders (chemically induced)
  • Early Termination of Clinical Trials
  • Humans
  • Multicenter Studies as Topic
  • Randomized Controlled Trials as Topic
  • Skin Neoplasms (chemically induced)
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: